Correction to: TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway (Journal of Pharmacology and Experimental Therapeutics (2014) 351:2 (352-358) DOI: 10.1124/jpet.114.215418);TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 352-358

  Chao, Ting Ting ^a   Wang, Cheng Yi ^a,b   Lai, Chih Cheng ^c   Chen, Yen Lin ^a   Tsai, Yi Ting ^a   Chen, Pao Tzu ^a   Lin, Hen I ^a   Huang, Yuh Chin T ^d   Shiau, Chung Wai ^e   Yu, Chong Jen ^f   Chen, Kuen Feng ^f  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d DUKE UNIVERSITY   (United States)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROCASPASE 9; PROTEIN KINASE B; TD 19; UNCLASSIFIED DRUG; AUTOANTIGEN; CASPASE 9; EGFR PROTEIN, HUMAN; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; QUINAZOLINE DERIVATIVE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; H358 CELL LINE; H441 CELL LINE; H460 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER CELL LINE; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; DRUG EFFECT; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84908146465     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.215418err     Document Type: Erratum

References (39)

1. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, et al.; SATURN investigators (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529.
2. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, and Cheng AL (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29:6257-6266.
3. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ, Huang JW, Kim I, and Shiau CW (2012) Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem 20:6144-6153.
4. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, Chen PJ, and Cheng AL (2011) Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther 10:892-901.
5. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, and Gonzalez EE (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13:300-308.
6. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al. (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15:5092-5100.
7. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, and Wang EH (2011) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18:857-865.
8. Hennequin LF, Boyle FT, Wardleworth JM, Marsham PR, Kimbell R, and Jackman AL (1996) Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent. J Med Chem 39:695-704.
9. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, and Chen KF (2012) Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 317:9-15.
10. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203.
11. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, et al. (2008) report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100:1672-1694.
12. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, and Chan EK (2013) Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 24:1638-1648, S1-S7.
13. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130:51-62.
14. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, and Chan EK (2010) CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 10:694-699.
15. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, et al. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101:793-805.
16. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, and Westermarck J (2011) ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE 6:e17979.
17. Lin YC, Chen KC, Chen CC, Cheng AL, and Chen KF (2012) CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 48:585-593.
18. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, and Chen KF (2013) Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 98:729-738.
19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
20. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ, Liu YQ, Pu JX, Xiao WL, Sun HD, et al. (2011) Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 6:e20159.
21. Mills I, Moreno FJ, and Fain JN (1984) Forskolin inhibition of glucose metabolism in rat adipocytes independent of adenosine 3', 5'-monophosphate accumulation and lipolysis. Endocrinology 115:1066-1069.
22. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413-1437.
23. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
24. Pallai R, Bhaskar A, Sodi V, and Rice LM (2012) Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 3:323-335.
25. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
26. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346.
27. Shreder KR, Wong MS, Nomanbhoy T, Leventhal PS, and Fuller SR (2004) Synthesis of AX7593, a quinazoline-derived photoaffinity probe for EGFR. Org Lett 6:3715-3718.
28. Soo Hoo L, Zhang JY, and Chan EK (2002) Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 21:5006-5015.
29. Tang WJ and Hurley JH (1998) Catalytic mechanism and regulation of mammalian adenylyl cyclases. Mol Pharmacol 54:231-240.
30. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, and Chen KF (2012) CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 14:R68.
31. Vaarala MH, Väisänen MR, and Ristimäki A (2010) CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29:136.
32. van Muijlwijk-Koezen JE, Timmerman H, van der Goot H, Menge WM, Frijtag Von Drabbe Künzel J, de Groote M, and IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A (3) receptor. J Med Chem 43:2227-2238.
33. Wang CY, Chao TT, Chang FY, Chen YL, Tsai YT, Lin HI, Huang YC, Shiau CW, Yu CJ, and Chen KF (2014) CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer 85:152-160.
34. Wong S, Mok W, Phaneuf S, Katz S, and Salari H (1993) Forskolin inhibits plateletactivating factor binding to platelet receptors independently of adenylyl cyclase activation. Eur J Pharmacol 245:55-61.
35. Xu P, Xu XL, Huang Q, Zhang ZH, and Zhang YB (2012) CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis. Med Oncol 29:1643-1647.
36. Yamanaka H, Oue T, Uehara S, and Fukuzawa M (2010) Forskolin, a Hedgehog signal inhibitor, inhibits cell proliferation and induces apoptosis in pediatric tumor cell lines. Mol Med Rep 3:133-139.
37. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, and Chen KF (2013a) Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 85:356-366.
38. Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, and Chen KF (2013b) Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS One 8:e55705.
39. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C, and Jia J (2010) pylori CagA upregulation of CIP2Ais dependent on the Src and MEK/ERK pathways. J Med Microbiol 59:259-265.